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Objective: To evaluate clinical outcome after accelerated partial breast irradiation (APBI) in the elderly after
high-dose-rate interstitial multi-catheter brachytherapy (HIBT).
Methods and materials: Between 2005 and 2013, 70 patients underwent APBI using HIBT. Catheter implant was
performed intra or post-operatively (referred patients) after lumpectomy and axillary sentinel lymph node dissection.
Once the pathological results confirmed the indication of APBI, planification CT-scan was performed to deliver
34 Gy/10f/5d or 32 Gy/8f/4d. Dose-volume adaptation was manually achieved (graphical optimization). Dosimetric
results and clinical outcome were retrospectively analyzed. Physician cosmetic evaluation was reported.
Results: With a median follow-up of 60.9 months [4.6 – 90.1], median age was 80.7 years [62 – 93.1]. Regarding APBI
ASTRO criteria, 61.4%, 18.6% and 20% were classified as suitable, cautionary and non-suitable respectively. Axillary
sentinel lymph node dissection was performed in 94.3%; 8 pts (11.5%) presented an axillary involvement. A median
dose of 34 Gy [32 – 35] in 8 to 10 fractions was delivered. Median CTV was 75.2 cc [16.9 – 210], median D90 EQD2 was
43.3 Gy [35 – 72.6] and median DHI was 0.54 [0.19 – 0.74]. One patient experienced ipsilateral recurrence (5-year local
free recurrence rate: 97.6%. Five-year specific and overall survival rates were 97.9% and 93.2% respectively. Thirty-four
patients (48%) presented 47 late complications classified grade 1 (80.8%) and grade 2 (19.2%) with no grade≥ 3.
Cosmetic results were considered excellent/good for 67 pts (95.7%).
Conclusion: APBI using HIBT and respecting strict rules of implantation and planification, represents a smart alternative
between no post-operative irradiation and whole breast irradiation delivered over 6 consecutive weeks.
Keywords: Breast cancer, Elderly, BrachytherapyIntroduction
With the increase in life expectancy, the incidence of
breast cancer is growing in the elderly population. Whole
breast irradiation (WBI), improving locoregional control
and overall survival, remains the standard of care after
breast conserving surgery, whatever the age of the patient
[1-3]. The management of adjuvant radiation therapy in
the elderly has become a medical and economic issue. In-
deed, a total treatment time of 6–7 weeks has been shown
to affect the observance [4] of WBI in the elderly patient* Correspondence: jean-michel.hannoun-levi@nice.unicancer.fr
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unless otherwise stated.sub-group mainly due to the high number of transporta-
tions. Moreover, it represents an important consumption
of resources with the problematic of saturation of radi-
ation therapy departments.
During the last decade, accelerated and partial breast ir-
radiation (APBI) techniques have emerged, as an alterna-
tive to whole breast irradiation (WBI) for patients with
early breast cancer and low risk of local recurrence [5-7].
The volume of breast tissue irradiated is smaller and the
course of treatment is shortened, which is particularly in-
teresting in the elderly [8]. Although consensus recom-
mendations have been published (Bethesda workshop [9],
ASTRO [10] and GEC-ESTRO [11]), APBI is not widely
accepted as an alternative to WBI due to the lack of longal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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WBI vs APBI. Concerns remain about the risk of local re-
currence requiring classically a salvage mastectomy.
Currently, different APBI techniques are used based on
intraoperative (electrons or low-energy photons) or post-
operative irradiation (brachytherapy or external-beam radi-
ation therapy). Potential advantages of a specific technique
over another are not clear, while the quality of the applied
technique and the experience of the medical staff remain
essential to achieve a good local control.
In this study, we investigated the results of a high-dose-
rate (HDR) interstitial multicatheter brachytherapy (HIBT)
as APBI in the elderly, in terms of clinical outcome.
Material and method
Patient features
From 2005 to 2013, 70 selected patients underwent a breast
conserving surgery for early breast cancer. All along the
study period, the 2004 Bethesda workshop and ASTRO
recommendations were used for the selection of elderly
women who could be good candidates for adjuvant APBI
using HIBT [9,10]. However, for few frail patients present-
ing comorbidity factors, APBI was proposed without strong
respect of the recommended APBI criteria. The protocol
was approved by the central review board of the Antoine
Lacassagne Cancer Center. Second conservative treatments
in case of ipsilateral breast cancer recurrence were not
considered.
Breast surgery
Axillary dissection concerned Level I and II axillary
lymph node area while sentinel lymph node biopsy alone
was also achieved with extemporaneous exam and con-
version to axillary dissection in case of positive biopsy.
Then, lumpectomy was performed. Quality of margins
was assessed by an extemporaneous pathological exam.
Four to five clips were clamped by the surgeon to mark
the tumor bed before closing the tumor bed cavity.
Brachytherapy
Catheters (Sharp Needles™; Nucletron, an Elekta com-
pany, Elekta AB, Stockholm, Sweden) were inserted
intra-operatively into the tumor bed according to the
pre-operative mammogram data and the definition of
the Clinical Target Volume (CTV) defined both by the
surgeon and the radiation oncologist. The geometry of
the implant was performed in respect to Paris system
recommendations [12].
Once the final pathological results confirmed the indi-
cation of APBI, post-operative planification CT-scan was
performed and the CTV was delineated taking into ac-
count a safety margin of 2 cm from the clips minus the
surgical margins described by the pathologist in the 6 di-
rections (latero-medial, antero-posterior, and cranio-caudal dimensions. The CTV was redefined as 5 mm
below the skin-surface, and 5 mm above the underlying
ribs for superficial and deep tumours respectively. In
case of inadequate pathological features for APBI,
brachytherapy was used as an anticipated-boost before
WBI. The planification was performed using Plato™ then
OncentraBrachy™ treatment planning systems (Nucletron,
an Elekta company, Elekta AB, Stockholm, Sweden).
Dose-volume adaptation was manually achieved using
graphical optimization. Dose constraints were: D90
(dose delivered to 90% of the CTV) > 105%, V100 (part
of the CTV receiving 100% of the prescribed dose) >
95%, V150 < 35%, V200 < 15% (with no confluence of
two consecutive V200 isodoses and V200 isodose diam-
eter < 10 mm) and DMskin (maximal dose delivered to
the skin) < 75%. Two protocols were applied delivering 2
fractions per day (6 hours apart) up to a total dose of
34 Gy (3.4 Gy/fraction over 5 consecutive days) or 32 Gy
(4 Gy/fraction over 4 consecutive days). Irradiation was
performed with an after-loading device using a 10 Ci 192Ir
source (Microselectron™; Nucletron, an Elekta company,
Elekta AB, Stockholm, Sweden). The irradiation was per-
formed in an out-patient hospitalization way.
Systemic therapy
Adjuvant chemotherapy or hormonal treatments were
proposed according to the protocols used in the Antoine
Lacassagne Cancer Center.
Follow-up
All patients were followed up closely. Clinical examination
was performed 1 month after HIBT and then every
6 month (alternatively by the surgeon and the radiation
oncologist. Mammograms were obtained yearly. Late tox-
icity was assessed according to CTCAE v.3 criteria [13].
Cosmetic results were assessed at every follow–up visit by
the physician according to the Harvard criteria [14]: excel-
lent (treated breast nearly identical to untreated breast),
good (treated breast slightly different from untreated), fair
(treated breast clearly different from untreated but not
seriously distorted), and poor (treated breast seriously dis-
torted). All patients were included in the follow-up. The
median follow-up was calculated from the day of last
brachytherapy fraction to the date of last follow-up.
Statistical analysis
Data were analyzed using the R 3.0.1 Windows software.
Quantitative data are represented as median, extreme,
mean and standard deviation. Qualitative data are rep-
resented as frequency, percentage and confidence inter-
val 95%.
Local recurrence-free survival (LRFS) was defined as
the time between the date of surgery and the date of ip-
silateral local recurrence. Metastatic disease free survival
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of surgery and the date of metastatic disease occurrence.
Specific survival (SS) and overall survival (OS) were de-
fined as the time between the date of surgery and death
from cancer or any cause respectively. These data were
estimated and plotted at different time intervals with
their 95% confidence using the Kaplan-Meier method.
Patients were censored at the time of death or at last
follow-up. The level of significance was set at a value of
p less than 0.05.
Results
Patients and tumor characteristics
With a median follow-up of 60.9 months [4.6 – 90.1], me-
dian age was 80.7 years [62 – 9 3.1] while 90% of the pa-
tients were older than 70 (Table 1). According to the APBI
ASTRO recommendations [10], 61.4%, 18.6% and 20%
were classified as suitable, cautionary and unsuitable re-
spectively. Among unsuitable patients, 1 patient under-
went a neo-adjuvant hormonal therapy, 2 pts could not lift
their arm (WBI was not technically feasible), 2 pts pre-
sented with a morbid obesity and underwent additional
supraclavicular fossa EBRT because of their nodal status.
Median tumor size was 11 mm [1.3 – 35], 8 pts (11.4%)
presented with axillary lymph node involvement, 16 pts
(22.8%) had a grade 3 tumor, hormonal status was negative
(ER-/PR-) for 6 pts (8.5%) while Her2 status was consid-
ered as overexpressed for 6 pts (8.5%).
Brachytherapy technique and dosimetric results
Among the 70 patients, the majority (92.9%) was im-
planted per-operatively. Five referred patients were im-
planted post-operatively. Median time interval between
surgery and brachytherapy was 12 days [5 – 105]. Median
number of needles and plans were 8 |5 – 16] and 2 [1-3]
respectively. Median total dose was 34 Gy [15-17] for a
median number of fractions of 10 [8-10]. The median
CTV was 75.2 cc [16.9 – 210]. Median EQD2 of the D90
using αβ = 4 was 43.3 Gy |35 – 72.6], median V100 was
95% [68.9 – 100] while median DHI was 0.54 [0.19 –
0.74]. Dosimetric results are summarized in Table 2.
Local control and survival rates
One patient experienced an ipsilateral multifocal local re-
currence (1.4%) associated with synchronous supraclavicu-
lar and metastatic relapses leading to a 5-year LRFS rate of
98.1% (95% CI [0.945; 1]) (Figure 1A). This 79 year-old pa-
tient belonged to the unsuitable group, underwent a neo-
adjuvant hormonal therapy because of an initial metastatic
disease doubt. The patient refused the chemotherapy pro-
posed at the time of relapse but accepted hormonal
therapy.
The 5-year MDFS rate was 96.3% ([95% CI [0.844; 1])
(Figure 1B). Taking into account the 79 year-old patientwho presented a synchronous local and metastatic relapse,
two additional patients developed a metastatic relapse.
One belonged also to the unsuitable group (positive nodal
status but she could not lift arms and additional supracla-
vicular EBRT was delivered). The second patient had an
exclusive metastatic relapse and belonged to the suitable
group. Characteristics of the patients who presented meta-
static recurrences are detailed in Table 3.
The 5-year SS and OS rates were 97.9% (95% CI [0.938;
1]) and 93.2% (95% CI [0.868; 0.999]) respectively (Figure 2A
and B). Four patients (5.7%) died from other causes, one
due to a head and neck cancer, tow due dementia, and one
due to cardio-vascular disease.
Toxicity
Acute side effects consisted mainly in breast pain, edema
or radio-dermatitis, while all the patients recovered spon-
taneously or with symptomatic medical management.
Thirty-four patients (48%) experienced at least one late
toxicity. Among these complications, 38 (79.2%) were
grade 1 and 9 (18.8%) grade 2. No grade 3 late side effects
occurred. Late skin and breast toxicity consisted mainly in
grade 1 sub-cutaneous fibrosis while dyspigmentation,
breast deformation and telangiectasia were also observed.
Toxicities are summarized in Table 4. Excellent or good
cosmetic results were observed in 67 patients (95.7%).
Discussion
Breast conserving treatment (BCT) is the standard of care
for early stage breast cancer. It consists of a conserving
surgery followed by whole breast irradiation (WBI) up to a
total dose of 45–50 Gy (delivered to the entire breast over
5 to 6 weeks with 1.8 to 2 Gy per fraction) with, in the ma-
jority of cases, a boost dose of 10–16 Gy to the tumor bed
[1,15,16]. Radiation therapy is a mainstay of this conserv-
ing approach, not only allowing a threefold reduction in
local recurrence but also improving overall survival [1-3].
Despite the advantages of BCT, adjuvant radiation therapy
is sometimes underused for some reasons (convenience,
patient age, distance from the radiation therapy center,
lack of social support structure, physician bias and fear of
radiation treatment). Studies have shown that 15% to 30%
of patients undergoing lumpectomy do not receive a
needed adjuvant radiation therapy [17,18]. This issue leads
to undertreat patients or inversely to perform total mast-
ectomy in patients who do not have access to adjuvant ra-
diation therapy. Indeed, the usual 6–7 weeks course of
irradiation lead to lack of observance and represents in
many countries an issue of access and cost with the out-
sized consumption of resources in terms of patient visits,
physician times and machines exploitation [19].
Regarding breast cancer in the elderly, this population
appears negatively affected by age at diagnosis, clinical
stage, and the presence of comorbidity factors [20,21]. Even
Table 1 Patients and tumor characteristics
Characteristics n %/range
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IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, OIC other
invasive carcinoma, DCIS ductal carcinoma in situ, LVI Lympho-vascular
invasion, PNI Peri-neural invasion, EIDC Extensive intra-ductal component,
HT Hormonal therapy, CT Chemotherapy.
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and its management has become a medical and economic
issue, rates of radiation recommendation in the elderly
have been steadily decreasing [22]. Recently, Hughes et al.
[23] updated the results of a phase III trial (CALGB 9343)
that randomized in the elderly who presented breast cancer
(T1N0, HR positive) lumpectomy plus Tamoxifen with or
without WBI. The authors confirmed that, at 10 years,
post-operative breast irradiation improved loco-regional-
free recurrence rate in women ≥ 70 year-old (98% vs 90%
with or without WBI respectively; p < 0.001), but, this local
control improvement did not translate into an advantage
in overall survival, distant disease-free survival or breast
preservation, considering that Tamoxifen alone was a rea-
sonable exclusive option for women ≥ 70 year-old. On the
other hand, it is well established that adjuvant breast irradi-
ation significantly decreases the rate of local recurrence
leading to a significant benefit in terms of breast cancer
death [1-3]. Those results can be also observed in the eld-
erly population in which Hancke et al. [24] described a
damaging impact on OS and DFS in case of WBI omission.
Regarding epidemiologic considerations, women aged
70 years and over who are currently in good health condi-
tion, have a median life expectancy of 15.5 years and half
of them will live much longer and will remain exposed for
enough time to the potentially preventable risks of a re-
lapse and specific death [25]. Taking all together, those data
lead to consider the adjuvant breast irradiation in the eld-
erly as a specific and key question that remains under de-
bate. Consequently, identifying a subset of women who
may not benefit from the addition of radiation therapy after
lumpectomy for early stage breast cancer has become an
important issue but still unresolved [26].
Table 2 Technical and dosimetric data
Data Mean Median Interval
#needles 9 8 [5 – 16]
#plans 2 2 [1 – 3]
CTV (cc) 82.3 75.2 [16.9 – 210]
Dose/f (Gy) 3.4 3.4 [3.4 – 4]
#fractions 10 10 [8 – 10]
Total dose (Gy) 34 34 [32 – 34]
Time interval S/B (d) 17.5 12 [5 – 105]
D90
Gy 3.7 3.7 [2.2 – 8.4]
% 106.2 107.1 [64.1 – 125.9]
EQD2 (Gy) 43.6 43.3 [35 – 72.6]
D100
Gy 2.6 2.7 [1 – 6.6]
% 74.8 77.5 [26 – 100.9]
EQD2 (Gy) 37.4 37.7 [26.9 – 59.8]
V100
cc 76.4 72.2 [16.4 – 192]
% 93.3 95 [68.9 – 100]
V150
cc 36.3 30.6 [7.4 – 96]
% 44.3 43 [22.1 – 81.2]
V200
cc 13.6 11.2 [3.2 – 51.6]
% 17.1 16.6 [9.4 – 47.3]
DHI 52.8 53.6 [18.8 – 73]
#needles: number of needles; #plans: number of plans; CTV: clinical target
volume; Dose/f: dose per fraction; #fractions: number of fractions; Time interval
S/B: time interval between surgery and brachytherapy; D90: dose delivered to
90% of the CTV; D100: dose delivered to 100% of the CTV; V100: part of the
CTV receiving 100% of the prescribed dose; V150: part of the CTV receiving
150% of the prescribed dose; V200: part of the CTV receiving 200% of the
prescribed dose; DHI: Dose Homogeneity index (1-V150/V100); EQD2:
equivalent dose at 2 Gy using an αβ = 4 for breast tissue and breast tumour.
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breast irradiation and 5 to 6 weeks of WBI, the concept of
accelerated partial breast irradiation emerged and has
been presented as a good option specifically for the elderly
population with breast cancer at low risk of local recur-
rence [8]. Indeed, irradiation is limited to the higher risk
area of local recurrence. By increasing the radiation frac-
tion size and decreasing the target volume and conse-
quently decreasing the volume of irradiated normal tissue,
this technique allows a shorter treatment time, which is
particularly interesting in the elderly leading to a potential
increase of radiation observance. Many techniques of APBI
have been developed: HIBT, balloon catheter brachyther-
apy, 3D-CRT (conformal radiation therapy) and intra-
operative radiation therapy (IORT). HIBT is one the first
APBI technique used and has the longest follow-up [27].With a 12-year median follow-up, Polgar et al. [28] re-
ported a 5-year LR rate of 4.7% with 77% of good/excellent
cosmetic results. In 2005, based on the Besthesda work-
shop recommendations [9], we started an APBI HIBT pro-
gram dedicated to elderly women. Later, ASTRO and
ESTRO recommendations strengthened our indications
[10,11]. In specific circumstances in which some eligibility
criteria were missing, we were led to propose APBI for pa-
tients with particular features that make a classical EBRT
impossible, such as functional disability to lift arms or mor-
bid obesity. It was the case of 4 patients out of the 14 be-
longing to the ASTRO unsuitable group. With a median
age of 81.4 years, our study is moreover representative of
the specific elderly population. With a 2.4% 5-year local re-
currence rate and 95.7% of excellent/good cosmetic results
without any grade 3 adverse events, our study compares fa-
vorably with the literature data [28-30]. The only one pa-
tient who experienced an in-breast recurrence belonged to
the ASTRO unsuitable group, and was not a good candi-
date APBI. It is essential to make a precise and rigorous se-
lection of the eligible patients for APBI [31].
Although consensus recommendations from ASTRO
[10] and GEC-ESTRO [11] have been published, the con-
cept of APBI is not clearly validated without consistent re-
sults in terms of evidence based medicine. Beside the
concept of APBI, it appears important to take into account
the technique used for APBI. From now, four different
studies were published focusing on APBI in the elderly.
Three of them consisted in phase II prospective trials using
either HDR brachytherapy based on a balloon device [32],
IORT using electron beam radiation therapy [33] and HIBT
[34]. All these studies confirmed that these different irradi-
ation techniques were feasible with encouraging results in
terms of clinical outcome. Furthermore, GERICO-03 study
specifically analyzed the functional status after APBI and
concluded that HIBT had no deleterious impact in the eld-
erly [34]. The fourth study was a non-randomized retro-
spective one recently published by Smith et al. [35]. In a
cohort of elderly women with breast cancer (mean age of
74.8), the authors compared APBI with brachytherapy and
WBI and reported worse long-term breast preservation and
increased complication rates for patients treated with
brachytherapy without any significant impact on survival.
The author advised “prompt caution over widespread appli-
cation of breast brachytherapy”. This assertion is acceptable
if we consider brachytherapy technique based on a balloon
device (Mammosite™) but not if HIBT is used [36-38]. Re-
cently, the same authors concluded, in an observational
study, that brachytherapy shows lesser breast preservation
benefit compared with EBRT and that the ASTRO suitabil-
ity criteria identify patients with the lowest absolute, but
not relative, risk of mastectomy [39]. However, it was a
methodologically objectionable observational study, using
again a single-lumen balloon applicator. Polgár et al. [40]
Figure 1 Kaplan-Meier curves for local recurrence free survival (A) and metastatic disease free survival (B).
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domized trial comparing APBI using HIBT versus WBI for
a selected group of patients with early stage breast cancer.
They authors reported similar 10-year results between
the two arms in terms of local control while significantly
better cosmetic outcome was observed in the HIBT arm.Table 3 characteristics of patients with relapse
Pt ASTRO group Type of relapse Age at surgery Histologic f












3 Unsuitable Synchronous 83.5 IDC





IDC: invasive ductal carcinoma; TTP: time to progression; D90: dose delivered to 90%
Dose Homogeneity index (1-V150/V100).Furthermore, the GEC-ESTRO Breast Cancer Working
Group recently reported the clinical outcome of a 2nd con-
servative treatment based on lumpectomy plus HIBT in
case of ipsilateral breast tumor recurrence [41]. The au-
thors noticed that, even in a context of accelerated partial
breast re-irradiation, late side effects were mainly grade1/2eatures TTP (months) Dose (Gy) D90 (%) V100 (%) DHI








27.3 34 69.7 75 0.44
3
-
of the CTV; V100: part of the CTV receiving 100% of the prescribed dose; DHI:
Figure 2 Kaplan-Meier curves for specific survival (A) and overall survival (B).
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sult was achieved in 85% of the patients.
The weaknesses of the present study are mainly repre-
sented by the retrospective status of this analysis and the
small number of patients but also, the very small num-
ber of events that did not allow performing uni/multi-
variate analysis researching prognostic factors for relapse
or side effect. Furthermore, it was not possible to com-
pare the 3 groups at risk (suitable, cautionary and un-
suitable) according to clinical outcome especially for
local recurrence rate.
Nevertheless, this study contributes to point out the
impact of the APBI technique used on clinical outcome.
Indeed, before going forward in the accurate analysis of
the phase III randomized trials that started to emerge, it
is important to keep in mind that the definitive valid-
ation (or not) of the APBI concept will be probably
strongly correlated to the technique used to achieve this
specific breast irradiation.Table 4 Type and grade of late toxicity according to the
CTCAE v.3 criteria [13]









While there is probably a sub-group of elderly women
who does not need any post-operative radiation therapy
for achieving good local control, this specific sub-group is
currently not well defined. So, for the elderly and regard-
ing clinical outcome, high-quality APBI using HIBT and
respecting implantation rules, represents a smart alterna-
tive between no post-operative irradiation and whole
breast irradiation delivered over 6 consecutive weeks.Consent
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